Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570583 · ClinicalTrials.gov registry record
Neurocognitive Outcomes of Depression in the Elderly
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 795
- Enrollment target
NCT00570583: Completed study, sponsored by Duke University.
NCT00570583 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 795 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570583 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 795 participants
- Enrollment target
Study Summary
Late-life depression (LLD) and cognitive impairment (CI) are significant public health problems among older adults, and their co-occurrence markedly increases disease burden and dementia risk. This highlights the importance of identifying and treating CI in LDD; however, current lack of reliable prognostic information from clinical, neuroimaging, and genetic data impedes research on targeted prevention and treatment. Two critical ways to close current knowledge gaps in predicting cognitive diagnostic outcomes of LLD involve: 1) increasing the number of diagnostic cases available to existing studies, and 2) using those studies to identify clinical, imaging, and genetic predictors that will improve future diagnosis. We intend to do both in the current proposal. We plan to study the following SPECIFIC AIMS: Aim 1: Identify baseline clinical-behavioral predictors of cognitive diagnostic outcomes in LLD. Working hypothesis: During acute LLD, CN will be associated with more frequent EOD and higher negative life stress than PCI and AD; PCI will be associated with EOD and higher frailty than CN and AD; AD will be associated with LOD, greater appetite loss, lower anxiety, and greater memory impairment than CN and PCI. Aim 2: Use multimodal neuroimaging at baseline to identify patterns associated with cognitive diagnostic outcomes in individuals with LLD. Working Hypothesis: CN will be associated with greater white matter integrity compared with PCI and AD; PCI will be associated with lower white matter integrity and network abnormalities in anterior cingulate cortex compared with CN; AD will be associated with lower hippocampal volume compared with CN and PCI. Aim 3: (exploratory): Explore interrelationships among candidate genes, cognitive diagnostic outcomes, and proposed phenotypic components relevant to LLD. Exploratory Hypotheses: 1) COMT val158met polymorphism will be associated with CN; 2) 5-HTTPRL and APOE ε2 polymorphisms will be associated with frailty; 3) gene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 1995-12 |
| Est. Completion | 2019-12-31 |
What the finished NCT00570583 record still lists
NCT00570583 is an observational study that tracks outcomes without assigning an intervention. The registered 795 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00570583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00570583 about?
NCT00570583 is a clinical study titled "Neurocognitive Outcomes of Depression in the Elderly". Late-life depression (LLD) and cognitive impairment (CI) are significant public health problems among older adults, and their co-occurrence markedly increases disease burden and dementia risk. This highlights the importance of identifying and treating CI in LDD; however, current lack of reliable pro...
What is the current status of trial NCT00570583?
This trial is currently completed. The enrollment target is 795 participants. The study started on 1995-12. Estimated completion is 2019-12-31.
Who is sponsoring clinical trial NCT00570583?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia